Novozymes separates biopharma, forms independent company

Novozymes separates biopharma, forms independent company

11:01 AM, 20th January 2016
Novozymes separates biopharma, forms independent company
Thomas Videbaek, executive VP, business development at Novozymes. (File photo)

BAGSVAERD, DENMARK: Novozymes said that it has separated its biopharma activities into an independent company called Albumedix. The new company will be fully owned by Novozymes.

“Over the past nine years, our work in albumin has resulted in a series of new discoveries and technologies, which have led to agreements with major pharmaceutical and biotech companies,” said Thomas Videbaek, executive VP, business development at Novozymes. “The business is in good shape with great prospects to make a real difference for patients all over the world. We believe it is now ready to be developed further outside Novozymes, where it will have the best possible growth conditions.”

Albumedix to accelerate Veltis for half-life extension

Albumedix will continue to develop its market leading position within recombinant albumin-based products and technologies. Albumin is a naturally occurring protein that can be found in human blood, the company said.

Named Recombumin, Albumedix’s recombinant albumins are used in the pharmaceutical industry to stabilize drugs and vaccines. For example, since 2006, Merck has used Albumedix’s solutions to produce two vaccines used to treat millions of children worldwide against measles, mumps, rubella and chicken pox, it said.

Albumin can also be used to extend the half-life of pharmaceuticals to prolong the drugs’ effect and Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis. In 2014, Veltis got its commercial breakthrough when GlaxoSmithKline launched a diabetes drug that utilizes the technology, allowing patients to dose weekly instead of daily. Albumedix has a growing pipeline of partner-driven drug candidates evaluating Veltis.

In addition to providing albumin-based solutions to the pharmaceutical industry, Albumedix will initiate the exploration of early stage clinical drug development based on its Veltis technology and relevant drug candidates, Novozymes said.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Chevron, ENN sign Gorgon LNG agreement

SAN RAMON, US: Chevron Corporation said that its Australian subsidiaries have signed a non-binding heads of agreement (HoA) with ENN LNG Trading Compa ...

Read more
Biesterfeld, Kelisema expand partnership in Germany

HAMBURG, GERMANY: Biesterfeld Spezialchemie GmbH said that it has taken charge of the distribution of Kelisema SRL’s product portfolio for the p ...

Read more
Amec Foster Wheeler CEO to step down after a 9-year stint

LONDON, UK: Amec Foster Wheeler said it has appointed chief financial officer, Ian McHoul, as interim CEO with immediate effect, following Samir Brikh ...

Read more
Nippon gains full ownership of OEM coatings maker Bollig & Kemper

OSAKA, JAPAN: Nippon Paint Holdings Co Ltd (NPHD) said that its consolidated subsidiary, Bollig & Kemper GmbH & Co KG (B&K), German automo ...

Read more
Shell quits major UAE gas project

LONDON, UK: Royal Dutch Shell PLC said that it will quit plans for a major gas development in the United Arab Emirates (UAE) amid a broad shake up of ...

Read more
ChemChina acquires 12 per stake in Swiss oil trader Mercuria

LONDON, UK: China National Chemical Corp (ChemChina) said that it has acquired 12 percent stake Mercuria Energy Group, one of the world’s larges ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X